Jones Trading downgrades Elicio Therapeutics to Hold

0 min read | Published on 16 Jun 2026, 10:39 PM |Updated on 16 Jun 2026, 10:39 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Jones Trading analyst Boris Peaker has downgraded Elicio Therapeutics from Buy to Hold. The revised rating signals a change in the investment firm's outlook regarding the company's stock performance.

*this image is generated using AI for illustrative purposes only.

Jones Trading analyst Boris Peaker has downgraded Elicio Therapeutics from Buy to Hold. The revised rating signals a change in the investment firm's outlook regarding the company's stock performance.

Rating Change Details

The adjustment moves Elicio Therapeutics out of a Buy recommendation, suggesting that the previous potential for significant upside may have diminished. The downgrade applies to the company's shares listed on NASDAQ under the ticker ELTX.

Analyst	Firm	Previous Rating	New Rating
Boris Peaker	Jones Trading	Buy	Hold

The Hold rating indicates that investors are advised to maintain their current positions rather than accumulate additional shares, based on the analyst's assessment.

What specific factors led to the diminished upside potential for Elicio Therapeutics?

How might this downgrade impact Elicio Therapeutics' stock price in the short term?

Are there upcoming clinical trial results or regulatory decisions that could influence future analyst ratings?

HC Wainwright raises Elicio Therapeutics price target to $23

0 min read | Published on 15 Jun 2026, 06:57 PM |Updated on 15 Jun 2026, 06:57 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

HC Wainwright & Co. analyst Robert Burns maintained a Buy rating on Elicio Therapeutics and raised the price target to $23 from $17.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Elicio Therapeutics and increased the price target to $23 from $17. The revised target reflects a more optimistic outlook on the company's stock performance.

Rating and Target Details

The decision to uphold the Buy rating accompanies a significant adjustment in the valuation expectations for Elicio Therapeutics. The new price target of $23 represents an increase over the previous target of $17.